HOME > SCIENCE > TESTING BY DEVICE TYPE > TISSUE ENGINEERING LOCATIONS | CONTACT US | SITEMAP
-
Testing by Device Type

Tissue Engineering

TEMPS or tissue engineering is a rapidly growing field of research. The goal for developers is to cultivate a targeted tissue or organ rather than replace it with a prosthetic device. In most cases, the cellular materials used will be human derived, and perhaps from the patient. Typically the cells are seeded onto a substrate and allowed to proliferate until an adequate amount of tissue or cells are available for transplant to the patient. At best, the final "device" is generally considered a combination product subject to multi-agency review and approval.

In vitro and in vivo models to evaluate the safety or compatibility of the cellular material are very specialized and specific to the cells being incubated. The evaluations of cellular materials fall outside the preview of ISO 10993, the primary international guidance for the evaluation of medical devices. The substrate or matrix materials used to "seed" the cellular materials are subjected to routine device evaluations. Typically these products are considered as implants that degrade or absorb, leaving only the cellular component behind. In other cases, the substrate or protective polymer is considered a permanent implant that allows the cells to function without rejection.

Standards and Regulation

The polymer matrix or substrate is subject to ISO 10993 evaluations. Various guidance documents have been approved by ASTM and other standards organizations for development, handling and control of the tissue or cellular component of the TEMPS.

Note: Processed cells or tissues such as a collagen, demineralized bone, porcine heart valves and so forth are considered medical devices and not TEMPS, and are subject to the requirements of ISO 10993.

Test Categories

The following test areas should be considered for a polymer substrate:

Characterization of Materials

  • Routine chemical characterization of potential extracted chemicals
  • Routine analysis of degradation products
  • Understanding of absorption and distribution of the polymer

R & D Function and Performance

  • Treatment or implant with a device seeded with cells similar to the human condition.
  • Final product implant or treatment to immunosuppressed models.

Biocompatibility

  • Cytotoxicity
  • Sensitization or allergenicity of aqueous and non-aqueous extracts
  • Intracutaneous Injection of aqueous and non-aqueous extracts
  • Acute Systemic Toxicity of aqueous and non-aqueous extracts
  • Muscle or Subcutaneous Implant to bracket clinical exposure
  • Subchronic Toxicity study under clinic-like exposure
  • Series of genotoxicity assays (generally 3)
  • Chronic Toxicity evaluation for long term study

Complete Sterility Assurance Program

  • Sterilization validation as dictated by the validation matrix and cellular components
  • Environmental monitoring
  • Packaging validation and shelf life testing

This list provides an overview of TEMPS that is an evolving area of medical research. Adequate guidance on how to evaluate the non-clinical biocompatibility of the entire device is still under development. Separate testing of the polymer carrier component and cellular elements is recommended. Consultation with responsible regulatory agencies is also recommended.

NEED HELP?

Tell us what you need.

Or call us:

866.666.9455 (within the U.S.)
419.666.9455 (outside the U.S.)